Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab plus platinum-doublet chemotherapy versus placebo plus platinum-doublet chemotherapy for perioperative treatment of resectable stage III non-small cell lung cancer
CTR20233392Phase 3Active
- Sponsor
- Sichuan Sigmaker Pharmaceutical
- Start
- Dec 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by Sichuan Sigmaker Pharmaceutical. Started Dec 2023; status: active.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20233392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233392.